Literature DB >> 25207063

In Vitro Effects of Ivermectin and Sulphadiazine on Toxoplasma gondii.

Melek Bilgin1, Tuba Yıldırım2, Murat Hökelek3.   

Abstract

OBJECTIVE: Ivermectin and sulphadiazine were tested individually to determine their in vitro effects on Toxoplasma gondii grown in human epidermoid larynx carcinoma (Hep-2) cell culture. STUDY
DESIGN: In-vitro study.
MATERIAL AND METHODS: Toxoplasma growth was quantities by an enzyme immunoassay performed directly on the fixed cultures, using a rabbit anti-T. gondii immunoglobulin G as the first antibody and a phosphatase-labeled anti-rabbit immunoglobulin G as the second antibody. For each drug, regression models were used to quantify the relationship between optical density values and antimicrobial agent concentrations in the cultures.
RESULTS: The 50% inhibitory concentrations (IC50) of ivermectin and sulphadiazine were found to be 0.2 μg/mL and 7.3 μg/mL after 48 h of exposure, respectively. None of the concentrations tested for each drugs demonstrated toxicity to Hep-2 cells after 72 h of incubation.
CONCLUSION: These results indicate that ivermectin significantly inhibited replication of the tachyzoites of T. gondii RH strain.

Entities:  

Keywords:  Hep-2; Toxoplasma gondii; in vitro; ivermectin; sulphadiazine

Year:  2013        PMID: 25207063      PMCID: PMC4116007          DOI: 10.5152/balkanmedj.2012.098

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  8 in total

1.  Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.

Authors:  Cynthia A Guzzo; Christine I Furtek; Arturo G Porras; Cong Chen; Robert Tipping; Coleen M Clineschmidt; David G Sciberras; John Y K Hsieh; Kenneth C Lasseter
Journal:  J Clin Pharmacol       Date:  2002-10       Impact factor: 3.126

2.  Enzyme immunoassay for evaluation of Toxoplasma gondii growth in tissue culture.

Authors:  A Merli; A Canessa; G Melioli
Journal:  J Clin Microbiol       Date:  1985-01       Impact factor: 5.948

3.  In vitro effects of folate inhibitors on Toxoplasma gondii.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 4.  Toxoplasmosis.

Authors:  Eskild Petersen
Journal:  Semin Fetal Neonatal Med       Date:  2007-02-23       Impact factor: 3.926

Review 5.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

6.  In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.

Authors:  Pascale Meneceur; Marie-Anne Bouldouyre; Dominique Aubert; Isabelle Villena; Jean Menotti; Virginie Sauvage; Jean-François Garin; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

7.  Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

8.  Toxoplasma gondii: virulence of tachyzoites in serum free media at different temperatures.

Authors:  M R Diab; M M El-Bahy
Journal:  Exp Parasitol       Date:  2007-07-13       Impact factor: 2.011

  8 in total
  2 in total

1.  Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro.

Authors:  Lais Pessanha de Carvalho; Thaisa Lucas Sandri; Edésio José Tenório de Melo; Rolf Fendel; Peter G Kremsner; Benjamin Mordmüller; Jana Held
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.